Phosphorus Metabolism in Hypopharynx Carcinoma and Resistance to Cisplatin
Author Information
Author(s): R. Tausch-Tremll, P. Kopf-Maier, F. Baumgart, B. Gewiese, D. Ziessow, H. Scherer, K.J. Wolf
Primary Institution: Klinikum Steglitz, FU Berlin
Hypothesis
The study investigates the phosphorus metabolism changes in a xenografted hypopharynx carcinoma following cisplatin treatment and compares three sublines with varying resistance levels.
Conclusion
The study found that changes in phosphorus metabolism detected by 31P NMR spectroscopy are specific to the tumor's response to cisplatin treatment.
Supporting Evidence
- The study identified a decrease in the phosphomonoester/phosphodiester ratio as an early marker of tumor regression.
- Changes in the 31P NMR spectra were correlated with the degree of tumor response to cisplatin treatment.
- Resistant tumor lines showed alterations in NMR spectra similar to those observed during uninfluenced tumor growth.
Takeaway
Researchers looked at how a type of cancer reacts to a drug called cisplatin, finding that the way the cancer uses phosphorus can show if the drug is working.
Methodology
The study used in vivo 31P NMR spectroscopy to monitor phosphorus metabolism in tumor sublines treated with different doses of cisplatin, alongside histological and cytokinetic analyses.
Limitations
The study primarily focused on a specific type of cancer and may not be generalizable to other cancers or treatment regimens.
Participant Demographics
The study involved male athymic mice (NMRI, nu/nu) as the model for xenografted tumors.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website